Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
flu
Biotech
Moderna's next-gen COVID vax surpasses approved version in ph. 3
Moderna’s next-gen COVID vaccine notched a higher immune response than its licensed counterpart, passing a phase 3 test.
Max Bayer
Mar 26, 2024 10:55am
Novo Nordisk Foundation sets up $260M vaccine initiative
Dec 18, 2023 11:14am
Moderna culls 4 clinical assets
Sep 13, 2023 5:58pm
Moderna's first seasonal flu shot candidate slides into clinic
Jul 7, 2021 10:39am
Janssen culls BARDA-funded flu phase 3 antiviral pimodivir
Sep 3, 2020 7:00am
Biotech builder ElevateBio reveals its first portfolio company: AlloVir
May 22, 2019 7:00am
